Pallavi D Annambhotla1,2, Brian M Gurbaxani3,4, Matthew J Kuehnert1, Sridhar V Basavaraju1. 1. Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2. Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA. 3. Office of the Associate Director for Science, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Abstract
BACKGROUND: In 2013, guidelines were released for reducing the risk of viral bloodborne pathogen transmission through organ transplantation. Eleven criteria were described that result in a donor being designated at increased infectious risk. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) transmission risk from an increased-risk donor (IRD), despite negative nucleic acid testing (NAT), likely varies based on behavior type and timing. METHODS: We developed a Monte Carlo risk model to quantify probability of HIV among IRDs. The model included NAT performance, viral load dynamics, and per-act risk of acquiring HIV by each behavior. The model also quantifies the probability of HCV among IRDs by non-medical intravenous drug use (IVDU). RESULTS: Highest risk is among donors with history of unprotected, receptive anal male-to-male intercourse with partner of unknown HIV status (MSM), followed by sex with an HIV-infected partner, IVDU, and sex with a commercial sex worker. CONCLUSION: With NAT screening, the estimated risk of undetected HIV remains small even at 1 day following a risk behavior. The estimated risk for HCV transmission through IVDU is likewise small and decreases quicker with time owing to the faster viral growth dynamics of HCV compared with HIV. These findings may allow for improved organ allocation, utilization, and recipient informed consent.
BACKGROUND: In 2013, guidelines were released for reducing the risk of viral bloodborne pathogen transmission through organ transplantation. Eleven criteria were described that result in a donor being designated at increased infectious risk. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) transmission risk from an increased-risk donor (IRD), despite negative nucleic acid testing (NAT), likely varies based on behavior type and timing. METHODS: We developed a Monte Carlo risk model to quantify probability of HIV among IRDs. The model included NAT performance, viral load dynamics, and per-act risk of acquiring HIV by each behavior. The model also quantifies the probability of HCV among IRDs by non-medical intravenous drug use (IVDU). RESULTS: Highest risk is among donors with history of unprotected, receptive anal male-to-male intercourse with partner of unknown HIV status (MSM), followed by sex with an HIV-infected partner, IVDU, and sex with a commercial sex worker. CONCLUSION: With NAT screening, the estimated risk of undetected HIV remains small even at 1 day following a risk behavior. The estimated risk for HCV transmission through IVDU is likewise small and decreases quicker with time owing to the faster viral growth dynamics of HCV compared with HIV. These findings may allow for improved organ allocation, utilization, and recipient informed consent.
Authors: Joshua Kimani; Rupert Kaul; Nico J D Nagelkerke; Ma Luo; Kelly S MacDonald; Elizabeth Ngugi; Keith R Fowke; Blake T Ball; Anthony Kariri; Jeckoniah Ndinya-Achola; Francis A Plummer Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: P P Reese; H I Feldman; D A Asch; S D Halpern; E A Blumberg; A Thomasson; J Shults; R D Bloom Journal: Am J Transplant Date: 2009-08-21 Impact factor: 8.086
Authors: Jefferson M Jones; Brian M Gurbaxani; Alice Asher; Stephanie Sansom; Pallavi Annambhotla; Anne C Moorman; Saleem Kamili; John T Brooks; Sridhar V Basavaraju Journal: Am J Transplant Date: 2019-05-10 Impact factor: 8.086
Authors: Yvonne M Kelly; Arya Zarinsefat; Mehdi Tavakol; Amy M Shui; Chiung-Yu Huang; John P Roberts Journal: BMC Med Ethics Date: 2022-03-05 Impact factor: 2.652